The upgrade of Passage Bio to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

PASG stock opened at $0.47 on Tuesday. Passage Bio has a 52-week low of $0.38 and a 52-week high of $1.79. The firm has a market cap of $29.04 million, a P/E ratio of -0.40 and a beta of 1.55. The ...

PASSAGE BIO, INC. earnings at a glance (GAAP ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Passage Bio, Inc. (NASDAQ:PASG – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for shares of Passage Bio in a research report ...

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on March 4, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...